Leptomeningeal Metastases in Solid Tumors
DOI:
https://doi.org/10.3889/oamjms.2014.111Keywords:
breast cancer, lung cancer, leptomeningeal metastases, metastatic disease, carcinomaAbstract
BACKGROUND: Leptomeningeal metastases are diagnosed in 1% to 8% of patients with cancer. The most common histology is leukaemia, lymphoma, breast carcinoma, lung carcinoma and melanoma. The aim of this study is to show the appearance of leptomeningeal metastases in lung and breast cancer with specific biological features.
AIM: The study is a review of two cases - breast and lung carcinoma with specific biological features who eventually have developed leptomeningeal metastases.
CASE PRESENTATION: Although CNS metastasis most commonly occurs in those with known systemic metastases, our patient had biological indolent disease (nor hormone negative or HER 2 positive and no metastatic disease) and still LM did occur. LM remains a devastating complication of cancer with classic presentation with multifocal neurologic signs and symptoms (like the case with lung cancer), but many patients also have evidence of impaired CSF flow, and hydrocephalus may be the only presenting manifestation of LM.
CONCLUSION: The prognostic factors associated with survival in patients with LM metastasis are not certain as well as right treatment for these patients which is still a big challenge. Due to the lack of randomized studies and especially of studies referring to one specific primary tumor, there is currently no generally accepted standard of care in the treatment of LM metastases.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
De Angelisb L, Posner J. Neurological complication in cancer. 2nd ed. New York, NY: Oxford University Press, 2008.
Clarke JL, Perez HR, Jacks LM, Panageas KS, Deangelis LM. Leptomeningeal metastases in the MRI era. Neurology. 2010;74:1449–1454. DOI: https://doi.org/10.1212/WNL.0b013e3181dc1a69
Le Rhun E, Tailibert S, Chamberlain M. Canceromatous meningitis: Leptomeningeal metastses in solid tumors. Surg Neurol Int. 2013;S265-S288. DOI: https://doi.org/10.4103/2152-7806.111304
Oechsle K, Lange-Brock V, Kruell A, Bokemeyer C, de Wit M. Prognostic factors and treatment options in patients with leptomeningeal metastases of different primary tumors: a retrospective analysis. J Cancer Res Clin Oncol. 2010;136:1729 DOI: https://doi.org/10.1007/s00432-010-0831-x
Park JH, Kim YJ, Lee JO, Lee KW, Kim JH, Bang SM, Chung JH, Kim JS, Lee JS. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era. Lung Cancer. 2012;76:387–92. DOI: https://doi.org/10.1016/j.lungcan.2011.11.022
Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW. Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol. 2012;106:303–13. DOI: https://doi.org/10.1007/s11060-011-0664-8
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7. DOI: https://doi.org/10.1200/JCO.2009.25.9820
Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, Massard C, Spielmann M. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004;15:1640–4. DOI: https://doi.org/10.1093/annonc/mdh432
Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809–17.
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC. Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. Cancer. 2012;118:5463–5472. DOI: https://doi.org/10.1002/cncr.27581
Lee S, Ahn HK, Park YH, Nam do H, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, Im YH. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809–17. DOI: https://doi.org/10.1007/s10549-011-1682-0
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7(2):382-5.
Lin N, Dunn IF, Glantz M, Allison DL, Jensen R, Johnson MD, Friedlander RM, Kesari S. Benefit of ventriculoperitoneal cerebrospinal fluid shunting and intrathecal chemotherapy in neoplastic meningitis: a retrospective, case-controlled study. J Neurosurg. 2011;115:730–6. DOI: https://doi.org/10.3171/2011.5.JNS101768
Chamberlain MC, Kormanik PA. Prognostic significance of coexistent bulky metastatic central nervous system disease in patients with leptomeningeal metastases. Arch Neurol. 1997;54:1364–8. DOI: https://doi.org/10.1001/archneur.1997.00550230037013
Scott BJ, Brown T, Van Vught V, Kim R, Fanta PT, Bazhenova L, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for the treatment of leptomeningeal metastasis from solid tumors. Journal of Clinical Oncology. 2012:30. DOI: https://doi.org/10.1200/jco.2012.30.15_suppl.2052
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, et al. Leptomeningeal metastasis from non-small cell lung cancer: Survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012;7:382-5. DOI: https://doi.org/10.1097/JTO.0b013e3182398e4f
Tetsumoto S, Osa A, Kijima T, Minami T, Hirata H, Takahashi R, et al. Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. 2012;17:155-9. DOI: https://doi.org/10.1007/s10147-011-0256-9
Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood-brain barrier. Cancer Treat Rev. 2013;39:261–9. DOI: https://doi.org/10.1016/j.ctrv.2012.05.006
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
